Merck KGaA's Healthcare CEO looking 'beyond treatment' to combat diabetes

17 May 2018

Belén Garijo has been the chief executive of the Healthcare business of German life sciences group Merck KGaA (MRK: DE) since 2015. Speaking to The Pharma Letter, she discusses her company’s quest to overcome the chronic disease

Diabetes is a highly competitive marketplace, with pharma majors and upstart biotechs alike jostling for position in a field saturated with therapies. But Merck has a history in this therapy area, as Belén Garijo points out — the company launched diabetes treatment Glucophage (metformin) in 1957, which has become the world’s most-prescribed oral antidiabetic.

"Our company’s aspiration is to go beyond the one dimension of just being a provider of medicines"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK